An article on Protein Design Labs Inc. in the May 24, 2001, issue of BioWorld Today should have reported that PDL just completed patient entry (not the trial) in a Phase III study of Zamyl (formerly SMART M195) for acute myeloid leukemia. PDL expects to have primary endpoint data by the end of the year, not be ready to file for approval, as was reported in the story.

Editor¿s note: The error has been corrected in BioWorld Online.

No Comments